

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

WAGNER ET AL.

Examiner: Webb, Walter E

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: 7 APRIL 2005

U.S. APPLICATION NO: 10/599,697

35 USC §371 DATE: 5 OCTOBER 2006

FOR: PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF
AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed July 5, 2007. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9308


Leslie Fischer
Attorney for Applicants
Reg. No. 58,393

Date: 3/26/09